ICU Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May 07, 2024 at 04:30 pm
Share
ICU Medical, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 566.66 million compared to USD 568.65 million a year ago. Net loss was USD 39.47 million compared to USD 9.81 million a year ago.
Basic loss per share from continuing operations was USD 1.63 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 1.63 compared to USD 0.41 a year ago.
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.
ICU MEDICAL, INC. 
